home All News open_in_new Full Article

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

− Approval Expands Use of VONVENDI to Include Routine Prophylaxis to Reduce the Frequency of Bleeding Episodes in Adults with Type 1 and 2 Von Willebrand Disease (VWD) and On-Demand and Perioperative Management of Bleeding in Pediatric Patients with VWD1 − VONVENDI is the Only Recombinant Von Willebrand Factor Replacement Therapy with Approved Indications in […]


today last month attach_file Other

attach_file Other
attach_file Other
attach_file Events
attach_file Economics
attach_file Science
attach_file Events
attach_file Other
attach_file Other


ID: 486780867
Add Watch Country

arrow_drop_down